"Russia Pharmaceuticals & Healthcare Report Q1 2015" is now available at Fast Market Research
New Healthcare market report from Business Monitor International: "Russia Pharmaceuticals & Healthcare Report Q1 2015"
[USPRwire, Fri Jan 09 2015] Russia's recent economic malaise will continue to act as a drag on foreign investment and limit the commercial opportunity for drugmakers. W e continue to believe that Russia's ageing population and significant disease burden will act to underpin pharmaceutical expenditure growth over the long term.
Headline Expenditure Projections
* Pharmaceuticals: RUB786.50bn (USD24.68bn) in 2013 to RUB857.79bn (USD23.79bn) in 2014; +9.1% in local currency terms and -3.6% in US dollar terms.
* Healthcare: RUB4,841bn (USD151.94bn) in 2013 to RUB5,172bn (USD143.46bn) in 2014; 6.8% in local currency terms and -5.6% in US dollar terms.
Risk/Reward Index : Russia has an RRI score of 55.5 out of 100, making it the seventh most attractive pharmaceutical market in Emerging Europe. Russia has fallen three places from its previous position of the fourth most attractive market, owing to a worsening business environment and a depreciating currency. Although Russia scores the highest for Industry Rewards, its overall score is moderated by its lower Risk score, highlighting the challenging operating environment in the country.
* Fresenius ended its joint venture with Binnopharm, citing the worsening business environment as the primary reason for its withdrawal from the agreement.
* US-based drugmaker Baxter International entered a manufacturing agreement with Russian biopharmaceutical company Biocad. Under the terms of the agreement, Baxter will give Biocad production techniques for the localisation of production stages of the dosage form, packaging and final stages of production of the drug Advate (antihemophilic factor [recombinant]). The agreement will be valid for a period of 10 years and has an option of further extension. The process of transferring production stages of the dosage form, packaging, and final production stages of the preparation for the needs of the Russian healthcare is expected to be completed by H118.
* Prime...
The Russia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Russia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Russian pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Russia to test other views - a key input for successful budgeting and strategic business planning in the Russian pharmaceutical and healthcare market.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
You may also be interested in these related reports:
